In AML, CLL, and mantle cell lymphoma, upregulation and reliance on BCLX and MCL1 were reported to account for venetoclax resistance [35,42,43,67]. This evidence concerns the gene BCL2L1 and B-cell chronic lymphocytic leukemia.